The cost-effectiveness of cholinesterase inhibitor treatment in patients with non-AD disease has been demonstrated for Lewy body dementia [64], but acetylcholinesterase inhibitors have not shown clinical benefit for patients with MCI [65]. This evidence concerns the gene BCHE and Lewy body dementia.